Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production
- 3 May 1999
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 9 (9), 1279-1284
- https://doi.org/10.1016/s0960-894x(99)00178-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Matrix metalloproteinase inhibitors 1998Expert Opinion on Therapeutic Patents, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitorNature, 1994
- Processing of tumour necrosis factor-α precursor by metalloproteinasesNature, 1994
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- Detection of Stromelysin and Collagenase in Synovial Fluid From Patients with Rheumatoid Arthritis and Posttraumatic Knee InjuryArthritis & Rheumatism, 1992
- A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomasNature, 1990
- Cloning of the genes for human stromelysin and stromelysin 2: differential expression in rheumatoid synovial fibroblastsBiochemistry, 1989
- Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3Biochemical Journal, 1989